International Journal of Hematology

, Volume 97, Issue 4, pp 491–497

Successful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era

Authors

    • Division of Hematology and Rheumatology, Department of Internal MedicineKinki University Faculty of Medicine
  • Jun-ichi Nishimura
    • Department of Hematology and OncologyOsaka University, Graduate School of Medicine
  • Takahiro Shimada
    • Division of Hematology and Rheumatology, Department of Internal MedicineKinki University Faculty of Medicine
  • Hirokazu Tanaka
    • Division of Hematology and Rheumatology, Department of Internal MedicineKinki University Faculty of Medicine
  • Kentaro Serizawa
    • Division of Hematology and Rheumatology, Department of Internal MedicineKinki University Faculty of Medicine
  • Yasuhiro Taniguchi
    • Division of Hematology and Rheumatology, Department of Internal MedicineKinki University Faculty of Medicine
  • Mitsuhiro Tsuritani
    • Department of Obstetrics and GynecologyKinki University Faculty of Medicine
  • Yuzuru Kanakura
    • Department of Hematology and OncologyOsaka University, Graduate School of Medicine
  • Itaru Matsumura
    • Division of Hematology and Rheumatology, Department of Internal MedicineKinki University Faculty of Medicine
Case Report

DOI: 10.1007/s12185-013-1302-3

Cite this article as:
Morita, Y., Nishimura, J., Shimada, T. et al. Int J Hematol (2013) 97: 491. doi:10.1007/s12185-013-1302-3

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired stem cell disorder characterized by intravascular hemolysis and thrombosis. The most serious complication is thrombosis, the risk of which is augmented by the hyper-coagulable state that occurs during pregnancy; despite this risk, however, young female PNH patients often desire to have a baby. We recently experienced two successful deliveries in PNH patients, who were treated with anticoagulant therapy during their pregnancies. Meanwhile, given the potential benefit of eculizumab (Soliris), a humanized monoclonal antibody against C5, in reducing thrombosis and hemolysis, it represents a promising therapeutic option for the treatment of pregnant PNH patients in combination with, or in replacement of, anticoagulant therapy.

Keywords

Paroxysmal nocturnal hemoglobinuriaPregnancyLow-molecular weight heparinEculizumab

Copyright information

© The Japanese Society of Hematology 2013